Latest Market News

Alterity Therapeutics has secured encouraging regulatory feedback from the FDA on its ATH434 Phase 3 program for Multiple System Atrophy, marking a critical step towards pivotal trial initiation.

Blue Star Helium has successfully raised A$10 million through an oversubscribed placement, positioning itself to accelerate production at its Galactica and Pegasus helium projects.

Variscan Mines announces the resignation of CEO Stewart Dickson and the appointment of Tom Kent as executive director, signaling a strategic shift following the San Jose Mine Restart Study.

State Gas Limited has decided against proceeding with the sale of its High Density Natural Gas Pilot Plant after failing to finalise terms, while its R&D tax incentive claim remains under extended review by the ATO.

Lincoln Minerals has secured all necessary approvals to begin a targeted drilling campaign at its Minbrie Copper Project in South Australia, aiming to unlock significant copper and base metal potential.

Atomo Diagnostics stands to gain significantly as Lumos Diagnostics’ FebriDx test secures FDA CLIA waiver approval, vastly expanding its US market potential. This regulatory milestone triggers substantial contracted revenues and prompts Atomo to ramp up production.

The Star Entertainment Group has locked in a binding refinancing agreement with WhiteHawk Capital Partners, securing US$390 million to refinance existing debt and boost liquidity. This move aims to stabilise the company’s financial footing ahead of key regulatory approvals and asset sales.

Impact Minerals has raised A$2 million through a strategic placement to advance its High Purity Alumina project and explore new industrial minerals opportunities in Western Australia.

Beacon Minerals has completed the sale of its MacPhersons Reward project to Forrestania Resources, receiving $5 million in cash and a substantial equity stake in Forrestania. This deal positions Beacon to sharpen its focus on core assets like the Lady Ida project while maintaining exposure to MacPhersons through its new shareholding.

Shriro Holdings has introduced a new dividend policy aiming to distribute 20-30% of net profit after tax annually, balancing shareholder returns with capital needs. The Board retains discretion over payments, factoring in franking credits and strategic priorities.

Aroa Biosurgery has completed its Symphony randomised controlled trial, demonstrating improved healing rates for diabetic foot ulcers compared to standard care. The preliminary results pave the way for clinical adoption and potential US reimbursement.

RocketBoots has secured a significant A$3.3 million activation contract with a leading multinational retailer, marking the start of a global deployment phase that complements its existing SaaS agreement and promises near-term revenue growth.